2020-11-20 08:00
Biovica, active in cancer diagnostics, today announced that positive DiviTum®TKa results from the European multicenter study PYTHIA will be presented at the world´s leading breast cancer conference, SABCS, in early December. The PYTHIA study...
2020-11-19 08:00
Biovica, active in cancer diagnostics, today announced that positive DiviTum®TKa results from a clinical study at the University of Nebraska Medical Center and Washington University School of Medicine, US, will be presented at the world´s leading...
2020-11-18 08:00
November 18, 2020 -- Biovica, active in cancer diagnostics, today announced that initial results from the PROMISE study (NCT03281902) will be presented at the San Antonio Breast Cancer Symposium (December 8-11, 2020). The PROMISE Study is evaluating the...
2020-11-17 15:35
Biovica, active in cancer diagnostics, today announced that new DiviTum®TKa results from a large SWOG Cancer Research Network study further strengthen DiviTum®TKa’s monitoring capabilities within metastatic breast cancer. The study, known...
2020-11-13 15:20 Regulatory
Biovica, active in blood-based cancer diagnostics, today announced that the company’s 510(k) submission to the US Food and Drug Administration (FDA) for the blood test DiviTum®TKa will proceed to substantive review when the COVID-19 related...
2020-10-30 08:30 Regulatory
Biovica, active in cancer diagnostics, today announced that the US Food and Drug Administration (FDA) has indicated that it is reallocating resources to COVID-19 impacting the timeline for completion of the review of Biovica’s 510(k)-submission...
2020-10-23 08:00
Biovica, active in cancer diagnostics, today announced that four abstracts based on studies using the blood test DiviTum®TKa have been accepted as posters at the world's largest breast cancer symposium, SABCS, in early December. The abstracts...
2020-09-25 10:00 Regulatory
Biovica, active in blood-based cancer diagnostics, today announced that the company has filed a 510(k) submission with the U.S. Food and Drug Administration (FDA). “The 510(k) submission is a major step towards bringing DiviTum®TKa to patients...
2020-08-27 17:10 Regulatory
The following resolutions were passed at the annual general meeting of Biovica AB (publ) on 27 August 2020 in Uppsala. Adoption of the accounts for the financial year 2019/2020 and discharge from liability The annual general meeting, AGM, resolved to...
2020-08-27 08:00 Regulatory Interim
Clinical validation completed, work with the FDA submission in the final phase Significant events during the fourth quarter Significant events after the end of the period CEO’s comments During the quarter, we took important steps towards achieving...

>4,500

Numbers of patients in studies

28

Publications

22

Pharma Projects

Are you a US resident?

Only US residents will be able to qualify for this program

No